Answers are grounded in this paper and cite their sources.
Despite the success of cervical screening, cancer of the cervix is the fourth most common cancer affecting women worldwide (CRUK 2014). Rates are particularly high in developing nations, which lack the requisite infrastructure for cytology and colposcopy-based screening, and in certain demographic groups, where the uptake of screening is poor. Recent research has focused on developing less invasive and potentially more acceptable means of identifying women at high risk of cervical intraepithelial neoplasia (CIN). Urinary human papillomavirus (HPV) testing has received particular attention because of the ease of obtaining samples and the opportunity that this affords for overcoming barriers to cervical screening, such as embarrassment and discomfort. The cross-sectional study performed by Leeman et al. (BJOG 2017;124:1356–63). adds to the body of evidence supporting the equivalent sensitivity of urinary HPV testing to both self-collected cervical samples and those obtained by a doctor, when performed using two sensitive polymerase chain reaction (PCR)-based tests. Although this in itself simply confirms the results of an earlier meta-analysis by Pathak et al. (BMJ 2014;349:5264), the true value of this study lies in its ability to correlate the presence of urinary HPV with histologically confirmed CIN, as all patients underwent a cervical biopsy. These data have been missing from most historical studies, preventing the assessment of the true value of urinary HPV testing for the detection of premalignant cervical disease. Leeman et al. found that almost every patient with CIN2 or worse had high-risk HPV in their urine, confirming the sensitivity of the test. The caveat to this, however, is that as a standalone test it was relatively non-specific, and could potentially lead to over-diagnosis and treatment if not combined with further investigations for women testing positive. Piyathilake et al. (Cancer 2016;122:2836–44) clearly demonstrated this in their larger study of 502 women, where only one in five women testing positive for high-risk HPV in their urine or cervix had CIN2 or worse. Where HPV testing is of particular value is in the reassurance that it gives women with a negative test; the same group found that the absence of high-risk HPV infection was truly associated with no disease in over nine out of ten cases. Before urinary HPV testing can be rolled out into routine screening, however, further data are urgently required concerning the accuracy and acceptability of urinary HPV testing in the general population, instead of the selected colposcopy referral population that has been the focus of studies so far. The prevalence of cervical HPV infection is lower in the general population, and this will influence the sensitivity and negative predictive value of the test. Recruiting ‘hard to reach’ groups is a priority of future research, as it is precisely these women who are most likely to benefit from its use in clinical practice. If urinary HPV testing overcomes barriers to cervical screening that prohibit its uptake by these women, it may become an important weapon in the fight against cervical cancer. None declared. Completed disclosure of interests form available to view online as supporting information. EC and SK are funded through a National Institute for Health Research (NIHR) Clinician Scientist Fellowship (award reference NIHR-CS-012-009). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. ■ Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
No takes yet. Share an insight, caveat, or question.
Blake et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: